{"id":"W4320912957","doi":"10.1136/bmjopen-2021-060536","title":"Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)","year":2023,"lang":"en","type":"article","venue":"BMJ Open","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Health Services and Policy Research","funders":"Cilag; Janssen Pharmaceuticals; Principia Biopharma; LEO Pharma; Medac; Radboud Universiteit; Argenx; Radboud Universitair Medisch Centrum; Incyte; Dermira; UCB Pharma; Regeneron Pharmaceuticals; Pfizer; Hexal AG; Celgene; Biogen; Sanofi; Amgen; Les Laboratories Pierre Fabre; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis; Dermatology Life Quality Index; Observational study; Quality of life (healthcare); Psoriasis Area and Severity Index; Internal medicine; Dermatology; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02312033,0.00349923,0.005498075,0.001670842,0.003454141,0.002485835,0.002875765,0.003684018,0.01201063],"category_scores_gemma":[0.01124646,0.001920741,0.004646084,0.002539102,0.002565863,0.001807753,0.002189488,0.003522366,0.003220062],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004469029,"about_ca_system_score_gemma":0.01461206,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00497592,"about_ca_topic_score_gemma":0.006367992,"domain_scores_codex":[0.9858591,0.009443373,0.00120946,0.001265658,0.001171466,0.001051017],"domain_scores_gemma":[0.9900252,0.001422573,0.002405442,0.001569909,0.002598637,0.00197817],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7728203,0.1070273,0.05133578,0.006485587,0.003069801,0.0005551041,0.001865119,0.005504445,0.003562682,0.001720809,0.01262022,0.03343289],"study_design_scores_gemma":[0.6390616,0.2024956,0.1225122,0.001171918,0.001576437,0.000216647,0.001303638,0.002787237,0.00164983,0.001412227,0.02544775,0.0003649967],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.0778081,0.0003192922,0.002024645,0.0002896242,0.0001433462,0.9118342,0.006003892,0.00006453993,0.0015124],"genre_scores_gemma":[0.03364298,0.000177247,0.00261392,0.0002259674,0.00006060725,0.9604796,0.002399001,0.000007732878,0.0003930013],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.02312033,"threshold_uncertainty_score":0.1222734,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1062548915769905,"score_gpt":0.4272371488332586,"score_spread":0.3209822572562681,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}